Name | Number of supported studies | Average coverage | |
---|---|---|---|
naive B cell | 5 studies | 18% ± 1% | |
classical monocyte | 3 studies | 22% ± 2% | |
precursor B cell | 3 studies | 28% ± 4% | |
B cell | 3 studies | 20% ± 4% | |
epithelial cell | 3 studies | 26% ± 5% | |
fibroblast | 3 studies | 19% ± 3% | |
dendritic cell | 3 studies | 23% ± 6% | |
GABAergic neuron | 3 studies | 26% ± 5% | |
glutamatergic neuron | 3 studies | 34% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 24% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2926.49 | 1445 / 1445 | 100% | 20.06 | 183 / 183 |
lung | 100% | 2939.16 | 578 / 578 | 100% | 25.81 | 1155 / 1155 |
ovary | 100% | 2520.46 | 180 / 180 | 100% | 33.41 | 430 / 430 |
prostate | 100% | 4162.51 | 245 / 245 | 100% | 68.52 | 502 / 502 |
stomach | 100% | 1970.04 | 359 / 359 | 100% | 22.70 | 286 / 286 |
breast | 100% | 2927.38 | 459 / 459 | 100% | 30.81 | 1117 / 1118 |
brain | 100% | 3648.91 | 2636 / 2642 | 100% | 35.38 | 705 / 705 |
intestine | 100% | 2881.73 | 966 / 966 | 100% | 23.97 | 525 / 527 |
uterus | 100% | 2785.95 | 170 / 170 | 100% | 22.20 | 457 / 459 |
bladder | 100% | 2835.33 | 21 / 21 | 99% | 22.47 | 501 / 504 |
skin | 100% | 2489.56 | 1809 / 1809 | 99% | 24.06 | 469 / 472 |
thymus | 100% | 2734.70 | 653 / 653 | 99% | 29.24 | 601 / 605 |
kidney | 100% | 2100.91 | 89 / 89 | 99% | 23.56 | 891 / 901 |
adrenal gland | 100% | 3352.41 | 258 / 258 | 99% | 27.56 | 227 / 230 |
pancreas | 98% | 1240.80 | 323 / 328 | 99% | 22.69 | 176 / 178 |
liver | 99% | 1031.92 | 224 / 226 | 92% | 10.65 | 372 / 406 |
adipose | 100% | 3263.37 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3428.68 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 22.47 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 19.72 | 29 / 29 |
muscle | 100% | 2493.06 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2552.61 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 20.00 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.95 | 1 / 1 |
heart | 98% | 2442.09 | 848 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 2206.86 | 906 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0097191 | Biological process | extrinsic apoptotic signaling pathway |
GO_0051896 | Biological process | regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0016567 | Biological process | protein ubiquitination |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_2000377 | Biological process | regulation of reactive oxygen species metabolic process |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0045637 | Biological process | regulation of myeloid cell differentiation |
GO_0010498 | Biological process | proteasomal protein catabolic process |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_1901525 | Biological process | negative regulation of mitophagy |
GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
GO_0045619 | Biological process | regulation of lymphocyte differentiation |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0006914 | Biological process | autophagy |
GO_0043408 | Biological process | regulation of MAPK cascade |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0071782 | Cellular component | endoplasmic reticulum tubular network |
GO_0005829 | Cellular component | cytosol |
GO_0005135 | Molecular function | interleukin-3 receptor binding |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0031267 | Molecular function | small GTPase binding |
GO_0005128 | Molecular function | erythropoietin receptor binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0030971 | Molecular function | receptor tyrosine kinase binding |
Gene name | RNF41 |
Protein name | E3 ubiquitin-protein ligase NRDP1 (RING finger protein 41) (RING-type E3 ubiquitin transferase NRDP1) RING-type E3 ubiquitin transferase (EC 2.3.2.27) Ring finger protein 41 E3 ubiquitin-protein ligase NRDP1 (EC 2.3.2.27) (RING finger protein 41) (RING-type E3 ubiquitin transferase NRDP1) |
Synonyms | NRDP1 SBBI03 FLRF |
Description | FUNCTION: Acts as E3 ubiquitin-protein ligase and regulates the degradation of target proteins. Polyubiquitinates MYD88. Negatively regulates MYD88-dependent production of pro-inflammatory cytokines. Can promote TRIF-dependent production of type I interferon and inhibits infection with vesicular stomatitis virus (By similarity). Promotes also activation of TBK1 and IRF3. Involved in the ubiquitination of erythropoietin (EPO) and interleukin-3 (IL-3) receptors. Thus, through maintaining basal levels of cytokine receptors, RNF41 is involved in the control of hematopoietic progenitor cell differentiation into myeloerythroid lineages (By similarity). Contributes to the maintenance of steady-state ERBB3 levels by mediating its growth factor-independent degradation. Involved in the degradation of the inhibitor of apoptosis BIRC6 and thus is an important regulator of cell death by promoting apoptosis. Acts also as a PRKN modifier that accelerates its degradation, resulting in a reduction of PRKN activity, influencing the balance of intracellular redox state. The RNF41-PRKN pathway regulates autophagosome-lysosome fusion during late mitophagy. Mitophagy is a selective form of autophagy necessary for mitochondrial quality control . . |
Accessions | ENST00000394013.6 [Q9H4P4-2] ENST00000552244.5 F8VSB6 ENST00000615206.4 [Q9H4P4-1] Q9H4P4 ENST00000552656.5 [Q9H4P4-1] F8VSE5 ENST00000551711.5 ENST00000549038.5 ENST00000549119.1 F8VSP7 F8VNZ6 F8VVY2 ENST00000547967.5 ENST00000345093.9 [Q9H4P4-1] |